4-methylbenzenesulfonic acid;N-propan-2-ylpropan-2-amine | 133080-79-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-methylbenzenesulfonic acid;N-propan-2-ylpropan-2-amine
• CAS: 133080-79-2
• 化学式: C₆H₁₅N*C₇H₈O₃S
• 分子量: 273.397
• InChiKey: VYJMORNNMMLXQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.27
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  82.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-methylbenzenesulfonic acid;N-propan-2-ylpropan-2-amine 在 三聚氯氰 作用下， 以 乙腈 为溶剂， 反应 0.5h， 生成 对甲苯磺酰氯
  参考文献：
  名称：

  使用氰尿酰氯从伯胺和仲胺衍生的磺酸盐一锅法合成磺酰胺

  摘要：

  描述了一种方便，温和且有效的一锅合成新磺酰胺的方法。在室温下，在氰尿酰氯，三乙胺为碱和无水乙腈为溶剂的情况下，伯胺或仲胺衍生的磺酸盐的反应以良好或优异的收率得到相应的磺酰胺。 一锅反应-磺酰胺-胺磺酸盐-氰尿酰氯-三乙胺

  DOI：

  10.1055/s-0029-1217020
• 作为产物：
  描述：

  对甲苯磺酸 、 二异丙胺 以 甲醇 、 水 为溶剂， 反应 0.25h， 生成 4-methylbenzenesulfonic acid;N-propan-2-ylpropan-2-amine
  参考文献：
  名称：

  使用氰尿酰氯从伯胺和仲胺衍生的磺酸盐一锅法合成磺酰胺

  摘要：

  描述了一种方便，温和且有效的一锅合成新磺酰胺的方法。在室温下，在氰尿酰氯，三乙胺为碱和无水乙腈为溶剂的情况下，伯胺或仲胺衍生的磺酸盐的反应以良好或优异的收率得到相应的磺酰胺。 一锅反应-磺酰胺-胺磺酸盐-氰尿酰氯-三乙胺

  DOI：

  10.1055/s-0029-1217020

文献信息

• 2' ,5' -Oligoadenylate analogs
  申请人：Koizumi Makoto

  公开号：US20050261235A1

  公开（公告）日：2005-11-24

  A 2-5A analog represented by the formula (1): wherein m is 0 or 1; n is 0 to 2; R 1 represents an alkoxy group having from 1 to 6 carbon atoms which may be substituted, an unprotected mercapto group, a mercapto group protected by a nucleic acid synthesis protecting group, or an alkylthio group having from 1 to 4 carbon atoms which may be substituted; R 2 , R 3 , R 4 , R 5 and R 6 represent an unprotected hydroxyl group, a hydroxyl group protected by a nucleic acid synthesis protecting group, an alkoxy group having from 1 to 6 carbon atoms which may be substituted, an unprotected mercapto group, a mercapto group protected by a nucleic acid synthesis protecting group, or an alkylthio group having from 1 to 4 carbon atoms which may be substituted; R 7 represents an oxygen atom, or a —O(CH 2 CH 2 O)q-group, wherein q is 2 to 6; R 8 represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms which may be substituted, or a 5′-phosphorylated oligonucleotide analog which has one hydroxyl group removed from the 5′-phosphoric acid group; E 1 , E 2 , E 3 and E 4 represent a naturally occurring or modified nucleic acid unit, or a pharmacologically acceptable salt thereof.

  一种由公式（1）表示的2-5A模拟物，其中m为0或1；n为0至2；R1表示具有1至6个碳原子的烷氧基，可以被取代，未保护的巯基，通过核酸合成保护基保护的巯基，或者具有1至4个碳原子的烷硫基，可以被取代；R2、R3、R4、R5和R6表示未保护的羟基，通过核酸合成保护基保护的羟基，具有1至6个碳原子的烷氧基，可以被取代，未保护的巯基，通过核酸合成保护基保护的巯基，或者具有1至4个碳原子的烷硫基，可以被取代；R7表示氧原子，或者-O(CH2CH2O)q-基团，其中q为2至6；R8表示氢原子，具有1至6个碳原子的烷基，可以被取代，或者从5'-磷酸基团中去除一个羟基的5'-磷酸寡核苷酸类似物；E1、E2、E3和E4表示天然或修饰的核酸单元，或其药理学上可接受的盐。
• Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog
  申请人：Koizumi Makoto

  公开号：US20100035976A1

  公开（公告）日：2010-02-11

  A method of treating a tumor or a viral disease by administering to a human the following 2′,5′-oligoadenylate analog: Wherein m is 0; n is 0 or 1; R 1 is alkoxy substituted by hydroxyl, mercapto, alkylthio substituted by hydroxyl or X 1 —X 2 —X 3 —S—; R 2 , R 3 , R 4 , R 5 and R 6 are hydroxyl, mercapto, alkylthio substituted by hydroxyl or X 1 —X 2 —X 3 —S—; R 7 is oxygen, sulfur, —NH—, or —O(CH 2 CH 2 O)q-, wherein q is 2 to 6, or oxyalkyleneoxy; R 8 is hydrogen or a 5′-phosphorylated oligonucleotide which has one hydroxyl removed from the 5′-phosphoric acid; E 1 is K 2 ; E 2 is K 1 ; E 3 is K 2 or K 3 and E 4 is K 1 , K 2 or K 3 ; K 1 is K 2 is K 3 is B is adeninyl; A is alkylene; D is alkyl or alkenyl; X 1 is alkyl or phenyl; X 2 is —C(═O)O—, —OC(═O)— or —C(═O)S—; and X 3 is alkylene.

  一种通过向人体内注射以下2′，5′-寡腺苷酸类似物来治疗肿瘤或病毒性疾病的方法：其中m为0；n为0或1；R1为烷氧基，被羟基，巯基，被羟基的烷基硫代基或X1—X2—X3—S—取代的烷氧基；R2，R3，R4，R5和R6为羟基，巯基，被羟基的烷基硫代基或X1—X2—X3—S—；R7为氧，硫，—NH—，或—O(CH2CH2O)q-，其中q为2至6，或氧烷氧基；R8为氢或一个5′-磷酸寡核苷酸，其5′-磷酸上有一个羟基被去除；E1为K2；E2为K1；E3为K2或K3，E4为K1，K2或K3；K1，K2和K3为B为腺苷基；A为烷基；D为烷基或烯基；X1为烷基或苯基；X2为—C(═O)O—，—OC(═O)—或—C(═O)S—；X3为烷基。
• Hindered-hydroxyl functional (meth)acrylate esters, copolymers containing them and compositions including same
  申请人：UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION

  公开号：EP0594109A1

  公开（公告）日：1994-04-27

  This invention relates to hindered-hydroxyl functional (meth)acrylate compounds and derivatives thereof and to processes for the preparation thereof. This invention also relates to hindered-hydroxyl functional (meth)acrylate-containing copolymers and to compositions including same. The hindered-hydroxyl functional (meth)acrylate-containing copolymers have utility in coatings, adhesives, inks, sealants, as well as in other end uses.

  本发明涉及受阻羟基官能团(甲基)丙烯酸酯化合物及其衍生物，以及其制备工艺。本发明还涉及含受阻羟基官能团（甲基）丙烯酸酯共聚物和包括其在内的组合物。含受阻羟基官能团（甲基）丙烯酸酯共聚物可用于涂料、粘合剂、油墨、密封剂以及其他最终用途。
• Hindered-hydroxyl functional (meth) acrylate monomers containing di (meth) acrylates and compositions including same
  申请人：UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION

  公开号：EP0690080A2

  公开（公告）日：1996-01-03

  This invention relates to hindered-hydroxyl functional (meth)acrylate monomers containing significant amounts of the corresponding di(meth)acrylates, and to compositions including same. The hindered-hydroxyl functional (meth)acrylate and di(meth)acrylate monomers do not require separation prior to polymerization and have utility in coating, adhesive, ink, and sealant compositions, as well as in other end uses.

  本发明涉及含有大量相应二（甲基）丙烯酸酯的受阻羟基官能团（甲基）丙烯酸酯单体，以及包括这些单体的组合物。受阻羟基官能团（甲基）丙烯酸酯和二（甲基）丙烯酸酯单体在聚合前无需分离，可用于涂料、粘合剂、油墨和密封剂组合物以及其他最终用途。
• NOVEL 2' ,5' -OLIGOADENYLIC ACID ANALOGUES
  申请人：Sankyo Company, Limited

  公开号：EP1568704A1

  公开（公告）日：2005-08-31

  A 2-5A analog represented by the formula (1): [wherein m is 0 or 1; n is 0 to 2; R1 represents an alkoxy group having from 1 to 6 carbon atoms which may have a substituent, a mercapto group, a mercapto group protected by a nucleic acid synthesis protecting group, or an alkylthio group having from 1 to 4 carbon atoms which may have a substituent; R2, R3, R4, R5 and R6 represent a hydroxyl group, a hydroxyl group protected by a nucleic acid synthesis protecting group, an alkoxy group having from 1 to 6 carbon atoms which may have a substituent, a mercapto group, a mercapto group protected by a nucleic acid synthesis protecting group, or an alkylthio group having from 1 to 4 carbon atoms which may have a substituent; R7 represents an oxygen atom, or a -O(CH2CH2O)q- group (q is 2 to 6); R8 represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms which may have a substituent, or 5'-phosphorylated oligonucleotide analogs which do not have one hydroxyl group on a 5'-phosphoric acid group; E1, E2, E3 and E4 represent a naturally occurring or modified nucleic acid unit], and a pharmacologically acceptable salt thereof.

  由式(1)表示的 2-5A 类似物： [其中 m 为 0 或 1；n 为 0 至 2；R1 代表具有 1 至 6 个碳原子且可能具有取代基的烷氧基、巯基、受核酸合成保护基保护的巯基或具有 1 至 4 个碳原子且可能具有取代基的烷硫基；R2、R3、R4、R5 和 R6 代表羟基、受核酸合成保护基团保护的羟基、具有 1 至 6 个碳原子且可能具有取代基的烷氧基、巯基、受核酸合成保护基团保护的巯基或具有 1 至 4 个碳原子且可能具有取代基的烷硫基；R7代表氧原子，或-O(CH2CH2O)q-基团（q为2至6）；R8代表氢原子、具有1至6个碳原子且可具有取代基的烷基，或在5'-磷酸基上不具有一个羟基的5'-磷酸化寡核苷酸类似物；E1、E2、E3和E4代表天然存在的或修饰的核酸单元]，及其药理学上可接受的盐。